Nationwide study of candidemia, antifungal use and antifungal drug resistance in Iceland, 2000-2011.
J Clin Microbiol. 2012 Dec 26;
Authors: Asmundsdottir LR, Erlendsdottir H, Gottfredsson M
Candidemia is often a life-threatening infection, with highly variable incidence between countries. We conducted a nationwide study of candidemia in Iceland 2000-2011, in order to determine recent trends in incidence rates, fungal species distribution, antifungal susceptibility patterns, and concurrent antifungal consumption. A total of 208 infection episodes in 199 patients were identified. The average incidence during the 12-years was 5.7 cases/100,000 population/year, which was significantly higher than during 1990-1999 (4.3/100,000/year; p=0.02). A significant reduction in the use of blood cultures was noted in the last three years of the study, coinciding with the economic crisis in the country (p<0.001). Age-specific incidence rates were highest among patients at the extremes of the age, 20.7/100,000 for <1 year of age and 18.1/100,000 for >60 years, respectively, and varied by gender. Age-specific incidence among males >80 years was 28.6/100,000/year and 8.3/100,000/year for females in this age group (p=0.028). The 30-day survival rate among adult patients remained unchanged compared to 1990-1999 (70.4% vs 69.5%, p=0.97). Candida albicans was the predominant species (56%), followed by C. glabrata (16%), and C. tropicalis (13%). The species distribution remained stable compared to previous decades. Fluconazole use increased 2.4-fold from 2000 to 2011, with no increase in resistance. In summary, the incidence of candidemia in Iceland has continued to increase but may have reached a steady state, and no increase in antifungal drug resistance has been noted. Decreased use of blood cultures towards the end of the study may have influenced detection rates.
PMID: 23269738 [PubMed - as supplied by publisher]